State of Alaska Department of Revenue Increases Holdings in Artivion, Inc. $AORT

State of Alaska Department of Revenue increased its stake in shares of Artivion, Inc. (NYSE:AORT) by 9.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,880 shares of the company’s stock after buying an additional 1,975 shares during the quarter. State of Alaska Department of Revenue owned about 0.05% of Artivion worth $711,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its position in Artivion by 4.1% in the first quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company’s stock valued at $42,460,000 after purchasing an additional 67,327 shares during the period. Next Century Growth Investors LLC raised its position in Artivion by 107.6% in the first quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock valued at $25,140,000 after purchasing an additional 530,122 shares during the period. Lord Abbett & CO. LLC raised its position in Artivion by 31.0% in the first quarter. Lord Abbett & CO. LLC now owns 401,904 shares of the company’s stock valued at $9,879,000 after purchasing an additional 95,202 shares during the period. Charles Schwab Investment Management Inc. raised its position in Artivion by 5.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 376,052 shares of the company’s stock valued at $9,243,000 after purchasing an additional 17,860 shares during the period. Finally, Invesco Ltd. raised its position in Artivion by 27.9% in the first quarter. Invesco Ltd. now owns 341,656 shares of the company’s stock valued at $8,398,000 after purchasing an additional 74,589 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Trading Down 0.6%

AORT opened at $40.50 on Wednesday. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $45.07. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of -96.43 and a beta of 1.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The business has a fifty day moving average price of $40.73 and a 200 day moving average price of $32.24.

Artivion (NYSE:AORT) last released its earnings results on Thursday, August 7th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm had revenue of $112.97 million during the quarter, compared to analysts’ expectations of $107.96 million. Artivion’s revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Sell-side analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Artivion news, CEO James P. Mackin sold 12,500 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $42.32, for a total transaction of $529,000.00. Following the completion of the sale, the chief executive officer directly owned 852,783 shares of the company’s stock, valued at $36,089,776.56. This represents a 1.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jean F. Holloway sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $44.37, for a total value of $443,700.00. Following the sale, the senior vice president directly owned 172,129 shares of the company’s stock, valued at approximately $7,637,363.73. This represents a 5.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 74,858 shares of company stock valued at $3,250,129 over the last quarter. Corporate insiders own 8.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on AORT. Stifel Nicolaus lifted their target price on Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, September 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research report on Saturday, September 27th. Canaccord Genuity Group lifted their target price on Artivion from $41.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, September 29th. Oppenheimer reaffirmed an “outperform” rating on shares of Artivion in a research note on Friday, August 8th. Finally, JMP Securities lifted their price objective on Artivion from $33.00 to $42.00 and gave the company a “market outperform” rating in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.13.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.